公开(公告)号：US20220396547A1

公开(公告)日：2022-12-15

申请号：US17120607

申请日：2020-12-14

Applicant: UNIVERSITY OF KANSAS ,  Oregon Health & Science University

Inventor： Sudeshna ROY ,  Paolo BERNARDI ,  Michael FORTE ,  Frank SCHOENEN ,  Justina SILEIKYTE

IPC: C07C235/42 ,  C07D413/12 ,  C07D261/18 ,  C07D295/135 ,  A61K31/415 ,  A61K31/42 ,  A61P25/00 ,  A61P21/00 ,  C07C235/38 ,  C07C235/56 ,  C07D203/04 ,  C07D211/14 ,  C07D231/14 ,  C07D295/185

Abstract: The present technology relates to compounds of any one of Formula I, II, IIa, III, IV, and/or V as described herein and their tautomers and/or pharmaceutically acceptable salts, compositions, and methods of uses thereof.

公开(公告)号：US20240067600A1

公开(公告)日：2024-02-29

申请号：US18122605

申请日：2023-03-16

Applicant: UNIVERSITY OF KANSAS ,  Oregon Health & Science University

Inventor： Sudeshna ROY ,  Paolo BERNARDI ,  Michael FORTE ,  Frank SCHOENEN ,  Justina SILEIKYTE

IPC: C07C235/42 ,  A61K31/415 ,  A61K31/42 ,  A61P21/00 ,  A61P25/00 ,  C07C235/38 ,  C07C235/56 ,  C07D203/04 ,  C07D211/14 ,  C07D231/14 ,  C07D261/18 ,  C07D295/135 ,  C07D295/185 ,  C07D413/12

CPC classification number: C07C235/42 ,  A61K31/415 ,  A61K31/42 ,  A61P21/00 ,  A61P25/00 ,  C07C235/38 ,  C07C235/56 ,  C07D203/04 ,  C07D211/14 ,  C07D231/14 ,  C07D261/18 ,  C07D295/135 ,  C07D295/185 ,  C07D413/12

Abstract: The present technology relates to compounds of any one of Formula I, II, IIa, III, IV, and/or V as described herein and their tautomers and/or pharmaceutically acceptable salts, compositions, and methods of uses thereof.

公开(公告)号：US20180282264A1

公开(公告)日：2018-10-04

申请号：US15524595

申请日：2015-11-04

Applicant: KU Innovation and Collaboration ,  Oregon Health & Science University

Inventor： Sudeshna ROY ,  Paolo BERNARDI ,  Michael FORTE ,  Frank SCHOENEN ,  Justina SILEIKYTE

IPC: C07C235/42 ,  A61P21/00 ,  C07D261/18 ,  C07D413/12 ,  C07D295/135 ,  C07D295/185 ,  C07C235/56 ,  C07D211/14 ,  C07D203/04 ,  C07C235/38 ,  C07D231/14

Abstract: The present technology relates to compounds of any one of Formula I, II, IIa, III, IV, and/or V as described herein and their tautomers and/or pharmaceutically acceptable salts, compositions, and methods of uses thereof.